Core Insights - The article highlights the growing focus and development of the synthetic biology and biomanufacturing industry in Jiangsu Province, China, emphasizing its strategic importance and the supportive policies in place [2][3]. Policy and Industry Support - Jiangsu Province has identified biomanufacturing as a key development area in its "14th Five-Year Plan," with specific policies aimed at fostering a robust industrial ecosystem [2]. - Local governments in cities like Nanjing, Suzhou, Wuxi, and Changzhou are increasing financial support and subsidies for synthetic biology enterprises [2]. Talent and Research Capabilities - Jiangsu boasts a strong talent pool with leading life sciences universities and research institutions, such as Nanjing University and Southeast University, contributing to advancements in key technologies like gene editing and enzyme engineering [2]. - The province ranks highly in the number of research papers and patents in critical technology areas [2]. Industry Chain Development - The synthetic biology industry chain in Jiangsu is well-structured, covering upstream technologies like gene synthesis and DNA storage, midstream platforms with fermentation and purification capabilities, and downstream applications in pharmaceuticals, agriculture, and materials [2][3]. - Wuxi and Taizhou are noted for their significant biomanufacturing capacity, accounting for over 30% of the national output [2]. Industrial Parks and Company Listings - Jiangsu is accelerating the establishment of synthetic biology industrial parks, including several innovation parks in the Yangtze River Delta region [3]. - A total of 80 companies from Jiangsu have been recognized in the "Top 500 Biomanufacturing Companies in China" list, showcasing the province's competitive landscape [3]. Upcoming Events and Future Plans - The "China Biomanufacturing Industry Map (2025)" will be released in August 2025, featuring over 500 representative companies [1]. - The Fourth Synthetic Biology and Green Biomanufacturing Conference will take place from August 20-22, 2025, in Ningbo, Zhejiang, focusing on key trends and innovations in the industry [17].

Core Viewpoint - The strategic investment by Tuoxin Pharmaceutical in Jinsan Biotechnology highlights the growing optimism in the anti-aging market, particularly in the industrialization of ergothioneine, a rare amino acid with significant health benefits [1][6][20]. Group 1: Strategic Transformation of Tuoxin Pharmaceutical - Tuoxin Pharmaceutical, established in 2001, has evolved into a benchmark enterprise in the nucleoside raw materials sector, focusing on the development of nutritional enhancers and health products [2][4]. - The company aims to deepen its core areas while expanding into the health sector, particularly in nutritional enhancers and health foods, to create new growth points [4][20]. Group 2: Jinsan Biotechnology's Technological Breakthroughs - Jinsan Biotechnology has achieved a significant milestone by producing ergothioneine with a purity of 99.99% and a monthly production capacity of 3-5 tons, drastically reducing raw material costs by 90% [6][8]. - The company has established a cGMP production standard platform, enabling it to surpass industry standards in ergothioneine purity [8][11]. Group 3: Clinical Research and Market Expansion - Jinsan Biotechnology has expanded the application of ergothioneine beyond traditional skincare to areas such as eye health, sleep health, and liver health, with several clinical studies underway [10][11]. - The company has seen a 428-fold increase in search popularity for its ergothioneine products on Xiaohongshu, indicating strong market demand [11][20]. Group 4: Industry Impact and Global Opportunities - The collaboration between Tuoxin Pharmaceutical and Jinsan Biotechnology signifies a transformative shift in China's biopharmaceutical landscape, moving from treatment-focused approaches to preventive health and wellness [17][20]. - Jinsan Biotechnology's involvement in setting industry standards and obtaining international certifications positions it as a leader in the global health market [18][20].

Core Viewpoint - Daosheng Biotech (Shenzhen) Co., Ltd. is a leader in bio-based pigments, specializing in the large-scale production of synthetic biological indigo using biosynthesis technology, with significant advantages over traditional chemical indigo [3][5]. Company Overview - Established in 2022, Daosheng Biotech is the first company globally to achieve large-scale production of synthetic biological indigo through biosynthesis technology, located in Guangming District, Shenzhen [3]. - The core team has extensive research experience in synthetic biology, multi-omics, microbial fermentation, and metabolic engineering [3]. - The company has developed a comprehensive technology platform for the production of natural indigo pigments, achieving a pilot production yield of 40g/L, with industrial production lines nearing completion [3][4]. Product Line - The product line includes various bio-based natural pigments such as indigo, black pigment, red pigment, and yellow pigment, applicable in textiles, food coloring, cosmetics, and pharmaceuticals [4]. - The company holds multiple patents covering key aspects of the entire industry chain, including strain modification, fermentation processes, and product purification [4]. Product Features - The synthetic biological indigo is produced with a purity of ≥40% and a bio-based content of 98%, certified by the USDA as a bio-based product [8]. - The dye exhibits excellent antibacterial properties, making it suitable for medical textiles and functional clothing [8]. Production Capacity - An industrial fermentation production line with a capacity of 8000 liters has been established, with an annual production capacity of 25 tons [9]. Applications - The bio-based pigment can be widely used in: 1. Eco-friendly dyeing agents in the textile industry 2. Coloring agents in the food industry 3. Functional additives in cosmetics and personal care products 4. Intermediate raw materials in pharmaceuticals [10]. Industrial Cooperation - The dyed fabrics using synthetic biological indigo show deep colors and excellent color fastness, with dry rubbing fastness rated at 4-5 and wash fastness rated at 5 [11].

Core Viewpoint - The article highlights a groundbreaking technology developed by Chinese scientists that enables the synthesis of sugar from carbon dioxide, significantly reducing the time and resources required compared to traditional methods [1][2]. Group 1: Key Breakthroughs - The technology breakthrough involves the artificial synthesis of hexoses (six-carbon sugars) from carbon dioxide, marking China's advancement in the field of artificial carbohydrate synthesis [2]. - In 2023, the team successfully synthesized hexoses, including glucose and other sugars, in just 17 hours, achieving a carbon conversion rate of 0.67 grams per liter per hour, which is over ten times more efficient than natural photosynthesis [3][8]. - By 2025, the team achieved direct synthesis of sucrose from carbon dioxide, with a product concentration of 14 grams per liter, representing a 20-fold increase in efficiency compared to hexose synthesis [4][8]. Group 2: Technical Advantages - The energy consumption for sucrose synthesis is only 2 ATP per sucrose, compared to 37 ATP in natural pathways, resulting in approximately 85% energy savings [9]. - The engineered enzymes allow for precise control over the synthesis of various sugars, addressing the challenge of controlling the stereochemistry of sugar molecules [9]. Group 3: Application Prospects - In the pharmaceutical sector, precisely synthesized sugar molecules are crucial for vaccines and anticancer drugs, with costs being only one-third of those derived from natural extraction [13]. - The industrial biotechnology sector consumes over ten million tons of glucose annually; utilizing carbon dioxide synthesis could reduce food consumption by 60% [14]. - The technology can consume 1.6 tons of carbon dioxide for every ton of sugar produced, equivalent to the annual emissions of three family cars, contributing to carbon neutrality efforts [15].

Core Viewpoint - The article highlights the upcoming SynBioCon 2025 event, focusing on the potential of synthetic biology and biomanufacturing, showcasing innovative research teams, technologies, and products in the field [2][5]. Group 1: Event Overview - The SynBioCon 2025 will take place from August 20-22 in Ningbo, Zhejiang, featuring a special session called the "Biomanufacturing Youth Forum" with nearly 30 presentations [2][10]. - The event aims to facilitate the exchange of innovative research outcomes and promote collaboration between researchers and industry stakeholders [2][14]. Group 2: Forum Details - The Youth Forum will include presentations from various universities and research institutions, such as Anhui University of Technology and South China University of Technology [4]. - The forum is designed to help attendees understand key scientific issues, solutions, and future development directions in the biomanufacturing sector within a 15-minute timeframe [3][14]. Group 3: Special Activities - A closed-door high-level seminar will discuss the trends and growth points of biomanufacturing as part of the event's agenda [11]. - The event will also feature project roadshows and technology showcases, inviting participation from leading parks and investment institutions [14][20]. Group 4: Thematic Discussions - The conference will cover various topics, including green chemicals, new materials, AI in biomanufacturing, and future food and agriculture [15][17][19]. - Specific discussions will focus on the development of bio-based materials, non-grain carbon source utilization, and the application of AI in enhancing biomanufacturing processes [18][22].

Group 1 - Synthetic polyamides are important industrial materials with applications in automotive manufacturing, oil pipelines, electronics, sports equipment, and medical industries, with a global market size exceeding 100 billion RMB [1] - China is the largest consumer market for polyamide materials, with an annual demand reaching several million tons [1] - Polyamide 6 (PA6) and Polyamide 66 (PA66) account for over 90% of the total production of polyamides [1] Group 2 - The production of core monomers for polyamides through chemical methods faces challenges such as harsh conditions and low reaction efficiency [2] - The development of biotechnological methods for synthesizing key chemical monomers like dicarboxylic acids and diamines is gaining industry attention [2] - Professor Wang Dan's team at Chongqing University is focused on the biosynthesis of key polyamide monomers, collaborating with various companies [2][4] Group 3 - Professor Wang Dan will present at the SynBioCon 2025 conference, discussing the biomanufacturing of polyamide materials and their applications in green low-carbon materials [3] - Multiple technological achievements related to biobased chemicals and materials will be showcased at the conference [4] Group 4 - The SynBioCon 2025 conference will focus on five key areas, including green chemistry and biomanufacturing, aiming to explore alternatives to petroleum-based raw materials [8]

Core Viewpoint - The article highlights the significance of bio-based 1,4-butanediol (BDO) as a sustainable alternative to petrochemical-derived BDO, emphasizing its potential to transform the chemical industry and reduce carbon footprints [1][4]. Group 1: Investment and Production - Qore, a joint venture between Cargill and Germany's HELM AG, has officially launched the world's largest bio-based BDO production facility with a total investment of $300 million, aiming for an annual production capacity of 66,000 tons [3][4]. - The facility will utilize locally grown dent corn within a 100-mile radius, marking a significant step in sustainable raw material sourcing [3]. Group 2: Applications and Partnerships - BDO is a crucial organic chemical used across various industries, including textiles, pharmaceuticals, and biodegradable plastics, due to its ability to produce high-value derivatives [4]. - LYCRA plans to use QIRA, the brand name for bio-based BDO, to enhance the sustainability of its fibers, potentially reducing its carbon footprint by up to 44% [5]. - BASF has entered a long-term supply agreement with Qore to incorporate QIRA into its product portfolio, aiming for sustainable chemical production [6]. Group 3: Technological Advancements - Traditional BDO production methods in China rely heavily on acetaldehyde and propylene glycol, which are energy-intensive and environmentally harmful [7][8]. - The bio-based BDO production process developed by Genomatica utilizes a one-step fermentation method, which is more efficient and environmentally friendly compared to conventional methods [10]. Group 4: Global Developments - Several companies are investing in bio-based BDO production, including: - Korea's SKC Group, which plans a $1 billion facility in Vietnam with an initial capacity of 50,000 tons per year [11]. - Jinfa Technology's bio-based BDO project in Liaoning, set to produce 10,000 tons by October 2024 [11]. - Other companies like Yuanli Chemical and Shandong Lande Biotech are also making strides in bio-based BDO production [11]. Group 5: Future Outlook - Despite the current higher costs of bio-based BDO compared to petrochemical alternatives, its competitive edge is expected to grow as oil prices remain high and production technologies improve [14]. - The article suggests that bio-based BDO could become a mainstream choice in the long term, especially with advancements in production processes and potential carbon trading policies [14].

Core Viewpoint - All-trans retinoic acid (ATRA) is a key active derivative of vitamin A with extensive clinical application value, but mainstream manufacturers like BASF and DSM still rely on traditional chemical synthesis methods, which pose environmental challenges and do not meet green chemistry requirements [1][3]. Group 1: Research Breakthroughs - The team from the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, achieved a breakthrough by engineering Saccharomyces cerevisiae to produce ATRA at a fermentation yield of 1.84 g/L, providing a green solution for constructing a self-controlled vitamin industry chain [3][8]. - The research utilized a multi-faceted metabolic engineering strategy, optimizing chassis construction, module selection, cellular factory upgrades, and fermentation processes to achieve this yield [8]. Group 2: Metabolic Engineering Strategy - The initial focus was on creating a high-yield chassis for β-carotene, the precursor for ATRA, by screening genes from Xanthophyllomyces dendrorhous, leading to the construction of the Car09 strain with a β-carotene yield of 129.4 mg/L [5][6]. - The best combination for ATRA synthesis was identified as a β-carotene dioxygenase from marine bacteria and mouse retinaldehyde dehydrogenase, achieving 98.1 mg/L ATRA, although significant residual β-carotene indicated limitations in synthesis [6][7]. Group 3: Industrial Adaptation and Optimization - Four-dimensional collaborative modifications were implemented to address efficiency bottlenecks, including overexpressing transcription factors to enhance endoplasmic reticulum activity, balancing NADPH/NAD⁺ levels, and improving substrate supply, resulting in a 49.2% increase in ATRA yield [7][8]. - The development of a two-phase extraction fermentation process, combining glucose growth with ethanol and galactose induction, led to the successful production of ATRA at 1.84 g/L in a 5L fermenter [8]. Group 4: Industry Conference - The SynBioCon 2025 conference, scheduled for August 20-22 in Ningbo, will focus on the intersection of AI and biological manufacturing, exploring trends in green chemistry, new materials, future food, agriculture, and cosmetic ingredients [10][12].

Core Insights - The Chinese biomanufacturing industry is projected to reach a scale of 1.01 trillion yuan in 2024, with a year-on-year growth of 15.4%. By 2030, the industry is expected to exceed 2.5 trillion yuan, with a compound annual growth rate (CAGR) of 16.8% [1]. Industry Developments - The DT New Materials Research Institute has been actively monitoring and supporting the progress and innovation in the synthetic biology sector since the release of the "China Synthetic Biology Industry Map (2023)" which includes over 300 listed companies [1]. - The upcoming "Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025)" will take place from August 20-22 in Ningbo, Zhejiang, where the "China Synthetic Biology Industry Distribution Map (2025 Edition)" will be announced, featuring over 500 representative biomanufacturing companies and their product information [1]. Event Details - The SynBioCon 2025 conference will focus on five key areas: AI + Biomanufacturing, Green Chemistry and New Materials, Future Food, Future Agriculture, and Beauty Raw Materials. It aims to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan and discuss innovative technologies and products that will sustain the industry's vitality [1][10].

Core Viewpoint - The article discusses the rapid development and potential of the biomanufacturing industry, highlighting its role in the Fourth Industrial Revolution and the significant growth opportunities it presents in various sectors, particularly in China [3][4]. Industry Overview - Biomanufacturing is defined as an advanced production method centered on industrial biotechnology, utilizing biological resources and processes to produce target products at scale [5]. - The global biomanufacturing industry is projected to reach approximately $12,190 billion in 2024, with a year-on-year growth of 7.4%, and is expected to exceed $20 trillion by 2030, with a compound annual growth rate (CAGR) of 8.4% [9]. Market Dynamics - In China, the biomanufacturing industry is anticipated to reach a scale of 1.01 trillion yuan in 2024, growing by 15.4%, and is expected to surpass 2.5 trillion yuan by 2030, with a CAGR of 16.8% [9][10]. - The top three segments in China's biomanufacturing industry in 2024 will be biopharmaceuticals, biological food, and bio-chemical products, with biopharmaceuticals remaining the largest segment [10]. Technological Advancements - The industry is experiencing a shift from traditional resource reliance to technology-driven approaches, with significant improvements in biomass resource utilization and equipment efficiency [8]. - Innovations in biopharmaceuticals, such as the development of bispecific antibodies and ADC drugs, have seen an annual growth of 65% in product pipelines [8][12]. Application and Impact - In the medical field, biomanufacturing technologies like 3D printing are enabling personalized implants, achieving gross margins of 75% [9]. - In agriculture, microbial fertilizers have improved corn yields by 12% while reducing chemical fertilizer usage by 30% [9]. Future Trends - The article outlines several key trends, including the restructuring of industrial ecosystems, regional layout changes, deepening technological revolutions, product innovation iterations, and capital factor restructuring [17][18][19]. - The integration of AI and biotechnology is expected to enhance production efficiency and product quality, with significant implications for the industry [18]. Strategic Recommendations - Companies are encouraged to build a three-dimensional competitive system focusing on technology research and development, scene innovation, and ecosystem construction [20]. - Local governments should create a supportive industrial service matrix to foster the growth of the biomanufacturing sector [20].